Federal Reports

Ethics Training

Medicare Part B pays a set amount to health care providers who furnish drugs to its beneficiaries. Certain eligible health care providers-generally, those that serve a disproportionate share of needy patients-are allowed to purchase drugs using the 340B Drug Discount Program, thereby receiving sizable statutory discounts. Past Office of Inspector General (OIG) work found that Medicare payments to providers for 340B purchased drugs substantially exceeded the providers' costs. Under the design of the 340B Program and Part B payment rules, the difference between what Medicare pays and what it costs to acquire the drugs is fully retained by the participating covered entities, allowing them to stretch scarce Federal dollars in service to their communities. However, some policymakers have questioned whether a portion of the savings mandated through the 340B Program should be passed on to Medicare and its beneficiaries.

To view the report, please click on the link below.

This is an audit of the NEA's balance sheets as of September 30, 2015 and 2014, and the related statements of net cost, changes in net position, and budgetary resources (financial statements) for the years then ended, and the related notes to the financial statements. The objective of the audit was to express an opinion on the fair representation of those financial statements. Additionally, the audit considered the NEA's internal control over financial reporting and tested the NEA's compliance with certain provisions of applicable laws, regulations, contracts, and grant agreements that could have a direct and material effect on its financial statements. The audit resulted in a clean opinion, with one significant deficiency and recommendation.